Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Pecs – page 4

346 clinical trials in Pecs, Hungary across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Pecs at a glance
346
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

346 trials in Pecs

Open in trial search

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Fesoterodine
  • Sponsor:Maplight Therapeutics Inc.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents with juvenile idiopathic arthritis.

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Pecs

What the registry says about research in the country

01 Respiratory Conditions

Clinical research focusing on innovative treatments for chronic rhinosinusitis and asthma, with studies evaluating new therapeutic approaches for both conditions with and without nasal polyps.

  • Uncontrolled Asthma Management
  • Nasal Polyps Treatment
  • Viral Lung Infections

Multiple trials investigating novel medications to improve respiratory symptoms and patient quality of life.

02 Cardiovascular Research

Groundbreaking studies in heart failure prevention and cardiomyopathy, exploring new therapeutic options for various cardiovascular conditions.

  • Heart Failure Risk Reduction
  • Hypertrophic Cardiomyopathy
  • Cardiovascular Disease Prevention

Advanced research aimed at reducing cardiovascular events and improving patient outcomes.

03 Autoimmune Disorders

Innovative research into treatments for systemic sclerosis and Sjögren's syndrome, focusing on novel therapeutic approaches for these challenging conditions.

  • Systemic Sclerosis Management
  • Primary Sjögren's Disease
  • Autoimmune Manifestations

Studies evaluating new biological treatments to address various autoimmune conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.